HRP20100372T1 - Farmaceutski sastavi neuroaktivnog steroida i njihova uporaba - Google Patents
Farmaceutski sastavi neuroaktivnog steroida i njihova uporaba Download PDFInfo
- Publication number
- HRP20100372T1 HRP20100372T1 HR20100372T HRP20100372T HRP20100372T1 HR P20100372 T1 HRP20100372 T1 HR P20100372T1 HR 20100372 T HR20100372 T HR 20100372T HR P20100372 T HRP20100372 T HR P20100372T HR P20100372 T1 HRP20100372 T1 HR P20100372T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- pregnan
- methoxymethyl
- imidazolyl
- hydroxy
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 11
- 150000003431 steroids Chemical class 0.000 title 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims abstract 4
- 230000036470 plasma concentration Effects 0.000 claims abstract 4
- 208000007848 Alcoholism Diseases 0.000 claims abstract 3
- 201000007930 alcohol dependence Diseases 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 3
- 208000020401 Depressive disease Diseases 0.000 claims abstract 2
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 201000000484 premenstrual tension Diseases 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 239000008187 granular material Substances 0.000 claims 2
- 239000013563 matrix tablet Substances 0.000 claims 2
- 239000000155 melt Substances 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000002969 morbid Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68890505P | 2005-06-09 | 2005-06-09 | |
| PCT/EP2006/005574 WO2006131392A1 (en) | 2005-06-09 | 2006-06-09 | Pharmaceutical compositions of a neuroactive steroid and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100372T1 true HRP20100372T1 (hr) | 2010-08-31 |
Family
ID=36790861
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100372T HRP20100372T1 (hr) | 2005-06-09 | 2010-07-02 | Farmaceutski sastavi neuroaktivnog steroida i njihova uporaba |
| HR20120264T HRP20120264T1 (hr) | 2005-06-09 | 2012-03-23 | Farmaceutski sastavi neuroaktivnog steroida i njihove uporabe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120264T HRP20120264T1 (hr) | 2005-06-09 | 2012-03-23 | Farmaceutski sastavi neuroaktivnog steroida i njihove uporabe |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20090131383A1 (ko) |
| EP (3) | EP2263675A3 (ko) |
| JP (2) | JP2008542419A (ko) |
| KR (3) | KR20100095661A (ko) |
| CN (1) | CN101193640A (ko) |
| AT (2) | ATE538797T1 (ko) |
| AU (1) | AU2006256851C1 (ko) |
| BR (1) | BRPI0612921A2 (ko) |
| CA (1) | CA2611430C (ko) |
| CY (2) | CY1110199T1 (ko) |
| DE (1) | DE602006013622D1 (ko) |
| DK (2) | DK2168585T3 (ko) |
| EA (1) | EA013744B1 (ko) |
| ES (2) | ES2380060T3 (ko) |
| HK (2) | HK1140947A1 (ko) |
| HR (2) | HRP20100372T1 (ko) |
| IL (3) | IL187813A (ko) |
| NO (1) | NO20076319L (ko) |
| NZ (1) | NZ562979A (ko) |
| PL (2) | PL2168585T3 (ko) |
| PT (2) | PT1888080E (ko) |
| RS (2) | RS51304B (ko) |
| SI (2) | SI1888080T1 (ko) |
| UA (1) | UA94909C2 (ko) |
| WO (1) | WO2006131392A1 (ko) |
| ZA (1) | ZA200709188B (ko) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108976272B (zh) | 2011-10-14 | 2021-05-25 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| ES2807264T3 (es) | 2013-04-17 | 2021-02-22 | Sage Therapeutics Inc | Esteroides neuroactivos 19-nor para métodos de tratamiento |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| HUE041369T2 (hu) | 2013-04-17 | 2019-05-28 | Sage Therapeutics Inc | 19-nor C3,3-diszubsztituált C21-N-pirazolil-szteroidok és eljárás ezek alkalmazására |
| CA3199003A1 (en) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CA3235088A1 (en) | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20170233433A1 (en) | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MX2017005002A (es) * | 2014-10-16 | 2018-01-23 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos del snc. |
| EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
| RS61530B1 (sr) | 2015-01-26 | 2021-04-29 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns |
| DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
| IL309259A (en) | 2016-07-11 | 2024-02-01 | Sage Therapeutics Inc | C17, C20 and C21 converted neuroactive steroids and methods of using them |
| JP7065825B2 (ja) | 2016-07-11 | 2022-05-12 | セージ セラピューティクス， インコーポレイテッド | Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法 |
| WO2019051264A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| US20200188358A1 (en) * | 2018-12-14 | 2020-06-18 | Praxis Precision Medicines, Inc. | Methods for the treatment of depression |
| KR20210105934A (ko) * | 2018-12-17 | 2021-08-27 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| CN113891715A (zh) * | 2019-03-04 | 2022-01-04 | 普拉西斯精密医药公司 | 围绝经期和绝经期的治疗方法 |
| MA56046A (fr) | 2019-05-31 | 2022-04-06 | Sage Therapeutics Inc | Stéroïdes neuroactifs et compositions associées |
| JP2022552808A (ja) * | 2019-10-02 | 2022-12-20 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｇａｂａ－ａ受容体陽性アロステリック調節因子と、ｎｍｄａ拮抗薬、ｎｍｄａ陰性アロステリック調節因子、またはｎｍｄａ部分作動薬との組み合わせ |
| WO2021168106A1 (en) * | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Deuterated neurosteroid |
| JP2024506942A (ja) * | 2021-02-18 | 2024-02-15 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態 |
| US20240148756A1 (en) | 2021-02-18 | 2024-05-09 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| EP4329751A1 (en) * | 2021-04-26 | 2024-03-06 | Praxis Precision Medicines, Inc. | Methods of treatment with neuroactive steroids |
| WO2023159035A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
| WO2023159094A2 (en) * | 2022-02-16 | 2023-08-24 | Praxis Precision Medicines, Inc. | PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE |
| WO2023164386A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2535202B1 (fr) * | 1982-11-03 | 1985-08-09 | Fabre Sa Pierre | Comprimes de theophylline a liberation controlee et leur procede de fabrication |
| US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
| US4884909A (en) | 1986-12-25 | 1989-12-05 | Canon Kabushiki Kaisha | Recording apparatus |
| IL112638A (en) * | 1994-02-14 | 2003-10-31 | Cocensys Inc | 3alpha-HYDROXYLATED PREGNANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| US7083808B2 (en) * | 1998-12-17 | 2006-08-01 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
| WO2000066614A1 (en) * | 1999-04-29 | 2000-11-09 | Purdue Pharma Ltd. | 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY |
| CO5210862A1 (es) * | 1999-09-15 | 2002-10-30 | Alza Corp | Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia |
| US6080736A (en) * | 1999-10-27 | 2000-06-27 | Janus Pharmaceuticals, Inc. | Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| US20060074059A1 (en) * | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
-
2006
- 2006-06-09 PT PT06754274T patent/PT1888080E/pt unknown
- 2006-06-09 ES ES10000305T patent/ES2380060T3/es active Active
- 2006-06-09 RS RSP-2010/0265A patent/RS51304B/sr unknown
- 2006-06-09 DE DE602006013622T patent/DE602006013622D1/de active Active
- 2006-06-09 PL PL10000305T patent/PL2168585T3/pl unknown
- 2006-06-09 EP EP10010923A patent/EP2263675A3/en not_active Withdrawn
- 2006-06-09 PL PL06754274T patent/PL1888080T3/pl unknown
- 2006-06-09 KR KR1020107018375A patent/KR20100095661A/ko not_active Application Discontinuation
- 2006-06-09 WO PCT/EP2006/005574 patent/WO2006131392A1/en active Application Filing
- 2006-06-09 EP EP06754274A patent/EP1888080B1/en active Active
- 2006-06-09 DK DK10000305.2T patent/DK2168585T3/da active
- 2006-06-09 CN CNA2006800200317A patent/CN101193640A/zh active Pending
- 2006-06-09 EA EA200800007A patent/EA013744B1/ru not_active IP Right Cessation
- 2006-06-09 AT AT10000305T patent/ATE538797T1/de active
- 2006-06-09 EP EP10000305A patent/EP2168585B1/en active Active
- 2006-06-09 RS RS20120109A patent/RS52199B/en unknown
- 2006-06-09 AU AU2006256851A patent/AU2006256851C1/en not_active Ceased
- 2006-06-09 ES ES06754274T patent/ES2344313T3/es active Active
- 2006-06-09 KR KR1020087000520A patent/KR20080017091A/ko active Search and Examination
- 2006-06-09 JP JP2008515150A patent/JP2008542419A/ja active Pending
- 2006-06-09 KR KR1020127005147A patent/KR20120028407A/ko not_active Application Discontinuation
- 2006-06-09 SI SI200630698T patent/SI1888080T1/sl unknown
- 2006-06-09 US US11/921,889 patent/US20090131383A1/en not_active Abandoned
- 2006-06-09 PT PT10000305T patent/PT2168585E/pt unknown
- 2006-06-09 DK DK06754274.6T patent/DK1888080T3/da active
- 2006-06-09 AT AT06754274T patent/ATE464054T1/de active
- 2006-06-09 UA UAA200800334A patent/UA94909C2/ru unknown
- 2006-06-09 BR BRPI0612921-8A patent/BRPI0612921A2/pt not_active IP Right Cessation
- 2006-06-09 SI SI200631289T patent/SI2168585T1/sl unknown
- 2006-06-09 CA CA2611430A patent/CA2611430C/en not_active Expired - Fee Related
- 2006-06-09 NZ NZ562979A patent/NZ562979A/en not_active IP Right Cessation
-
2007
- 2007-10-25 ZA ZA200709188A patent/ZA200709188B/xx unknown
- 2007-12-02 IL IL187813A patent/IL187813A/en not_active IP Right Cessation
- 2007-12-07 NO NO20076319A patent/NO20076319L/no not_active Application Discontinuation
-
2008
- 2008-08-18 HK HK10107380.1A patent/HK1140947A1/xx not_active IP Right Cessation
- 2008-08-18 HK HK08109178.7A patent/HK1118202A1/xx not_active IP Right Cessation
-
2010
- 2010-07-02 HR HR20100372T patent/HRP20100372T1/hr unknown
- 2010-07-09 CY CY20101100642T patent/CY1110199T1/el unknown
-
2011
- 2011-02-08 IL IL211114A patent/IL211114A/en not_active IP Right Cessation
- 2011-11-07 IL IL216194A patent/IL216194A/en not_active IP Right Cessation
-
2012
- 2012-03-21 CY CY20121100298T patent/CY1112499T1/el unknown
- 2012-03-23 HR HR20120264T patent/HRP20120264T1/hr unknown
- 2012-05-04 US US13/464,369 patent/US20120276196A1/en not_active Abandoned
- 2012-07-23 JP JP2012162303A patent/JP2012229261A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100372T1 (hr) | Farmaceutski sastavi neuroaktivnog steroida i njihova uporaba | |
| WO2007000778A3 (en) | Modified release pharmaceutical compositions on the basis of two polymers and processes thereof | |
| ME00482B (me) | Čvrste farmaceutske kompozicije koje sadrže pregabalin sredstvo za formiranje matriksa i sredstvo za bubrenje | |
| BRPI0406996A (pt) | Formas de dosagem sólida via transmucosa oral sem açúcar e sua utilização | |
| ES2351947T3 (es) | Formulaciones orales de liberacion controlada de un inhibidor de la enzima convertidora de interleucina-1-beta. | |
| WO2006017852A3 (en) | Pharmaceutical compositions for controlled release delivery of biologically active compounds | |
| WO2007048219A3 (en) | Sustained drug release composition | |
| WO2008014175A3 (en) | Granular pharmaceutical compositions | |
| NZ597109A (en) | Tablet composition having favorable dissolution property useful as an anticoagulant | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| WO2010103544A3 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| WO2007017331A3 (en) | Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin | |
| WO2007025182A3 (en) | Drug compositions containing controlled release hypromellose matrices | |
| WO2008062475A3 (en) | Pharmaceutical compositions of ursodiol | |
| ATE491447T1 (de) | Flavonoide und tocotrienole enthaltende zusammensetzungen und deren verwendungen | |
| WO2008027340A3 (en) | Topical ophthalmic formulations | |
| WO2008122994A3 (en) | Stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof | |
| EA200701525A1 (ru) | Фармацевтическая полимерная композиция для перорального введения тербуталина сульфата с контролируемым высвобождением | |
| MXPA06007511A (es) | Revestimientos de granulos de farmaco que imparten resistencia a la embarradura durante la compresion mecanica. | |
| AR074689A1 (es) | Formulaciones farmaceuticas de desintegracion rapida pre-compactadas de compuestos con baja biodisponibilidad oral. proceso de preparacion | |
| PT1499278E (pt) | Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa | |
| WO2007119249A3 (en) | Pharmaceutical compositions of cefixime | |
| JO2440B1 (en) | Formulation of oral pharmaceutical polymers for controlled release of terbutalate sulfate. | |
| NZ620418A (en) | Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections |